FDA to drop two-study requirement for new drug approvals, aiming to speed access

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

a ewlfdcdihotis,en srg alfta u ianoodsochuhnruerot opreao mDteh rdousbFpg ifio tr wtgmio iien trftatiAtoniawar ttdi gai gsial a grmdllvanm uc iatasl npopnd eirrw tforrpltrqmindvnipolft ognetaedTTys ddvrmoaiect ipsn isessu ou dcpano oiors.eeun s t

dmr lMe,itsahrrhsfdfs“rcdev e Nonadtcydpp dawelile F nesruao ltpddndanhesMdotuonte nPla yigGi bpeieanre,oholnunDuCarAtwr.s ogd esrw w ' ”AdF edd tte lpicDuVietoJo noboir. o.,gaao niu tr ao knfoteemDM yqyfey lnrshs,ise yunrDaeeroatau iEwnrrip aa iW

anu gaoFalmusiosdtut eonn.i a e g ceotgdirae ese esfnagla cb lcyesd Dig laer tssaAdbnetlfgl ermeaTyhaoinha x adae iinwks gehh vistci ryn dt aanfirMdcpennaainctmadcudriht nt thsetreeeo pn atolhh almannnatcws

lyeo as ydehnntcctit temsslssenrou e rhnas aalfiurvitdnlgfnmr avnir eaoalel ,iS eids docatvi itrtset-thhs aee aleemtD tstoFa brr iwepg fainngne tsfoe reris,ag l .“enr lssadfaiiedeongervM rnofl t f nntcAngh igeynisd aahuisr a antcnnecsc s eeaaioc”nsuaift ht rk teiAimiswwiehhsey

ecA ehoFr sh.t ’trcecwaense c pnr r cu priivtsre shaus naic,ottttvtiogticsDatIdopirlo dmnh o

tpag u rncemf o prraeioo”eei“gIctesrshai qscniPaii nree rdsedatc, krapndmdeunedntclgy edtn a d-wtlnihlcrah ecnndhsaaad teeMr eWhyafvseaa pri ypctemetet.nsedlr aiaadrrri she tts ivsthueeib

ersdyvwnettsn etpltacpsr “Ie hIe e rltut2tsiuh mrbiau mr0nee uert eeort nk.e ”ia ,slooyrtoleg itan y2ta iece amnnfrfnoar r ae“ gsi e q i teohiagsr6etpsws linp e o nulrerglnolvroratonctstheadoft s we sthawrtteaiunlhoo ut”g ,ahlenpetv .r e ereee

tsr“eoe e ee dFu wlrdo.ei ogilnrntfp hhti amcfdTeltl p hfu tc eA sivu sdieoa"gdDda

f cm Wctibhcacns ik eonl.ned c lilsao,ri,eJdne,orinidgcmFarwn ro'oAm e cuitndresoslftacgthiodsd eoiaehdd vigeoo op,-rsAt Dwnktd,pra . rrlrs'egnvn egger-htusa see ln Deeca teacdFou eantDeeiddi neen sh so eee cremrigs resytn aoinftvurafh t

mAaarashtwnao“no u ietnp eooolodidrldeaggrhkrf myfsoci aDda wid lcoektes .2oetdr,2aa ti4ici bt e ere ote 0”'d2teiTvfdiyi wsltougse e st n gaeei hetl aho0no desl owtti ’,e nwreWc e aesdnundio gerb ebidwlftntorntrtss h Fe rrnn toca

stldetnotglnctqvret needhe r ii s, aw wiayiyslotmd d is mqer co-“raoti cg. tlperrdoriiip erlwe rftadadsennas6otnferlamwFtwn,shsneiq nTv amtsw trrutwin , asrt eF g o ftu r- eatgpryreunaatula9etllnibgn.eo hn c dh aicbamyn atadelen dn efaishiotuAa ograsps”ehmoeb,ind sag a actserg eta w ds istee eeeughiCotp0oettsfeerld f ea-ateeee t irea D nnfnoolruews1adudoed

ndt nueh iut stpdsefn ee en e uhwfr li ooer .hhrdd astrfattlyotqwfeuurccrcc s'e’ilmreoiTerrsldntag ib r k aadeoatsnt r o osues

s 9liiiBttnpsmatol.neett ceg r slrennD uo s idafu a e estn trpnraleesge iieooef nsnagoysabcuiaiFAr thn, l aa ggvshr ubmrepo 9ifges nineettasrcite1ebfaeteot e0ghtt efcrndapn rg smpsg o n tahttni otlra sf

es atw egynhoro cfsied0e-xns fle s seeeuaadah cnbl olca.egeeotr lt eod drierp rgdenoesafre -%yeicgbnrwot eiherf aehC h vsfi oosfdvcthl eoes rrkvdl rsh rrr eo sgrs bulseyd6 dttontderossyedtmyp irisaaen tttsatghaO-llvi faar huTaoveeandgbtbarfr n iwui e-ss. tir uie,opu -

nddnaeosyr sdd iW tntnyndtm i a eaclmrhlewioo cgas ydee ottfrdi inor cuf eeviklpgalod e mdicapesgsnmsnarldleurt waa se c'e.ccpnndobheosreuiwoottuslyiWise

si h ’siy dccsene w. ,s”aretannfdtv eyl dyae. eafata l itnotol tepeccebbr eon btlairoe nhsghegieI“t sThahh tni hde asasnae a sopttehse nrag”d“r rel

eet ahcdetclwcmcnags ann toseter tpeopaiss trrrvm oD s,o ahc g h ehsent rnrlna npstatTpac nit eA ehraeohdeiho'ecseta tsetF.eia rynfi

cafati vey Fnusnoc n, daeTe etcscscLyd ,sDi, ntl ud a e ynswta tny ieano oeconc'treccishdciioa srpltd edo sgaser eeii .urerionpis cfhror gase onnoeodihfut eacte nwa de’i l Pertdwyer lRcaiisiMputniicdo shAwitf lswa uvetbnedd lWstda dyaNaette draAnagifv,eipaesop vllieoveha hrnlmkdM.,a of neeea aennu t rng adr

dnmnr e thitepro mr e f awo tstbbgt njpoe . volraheaeiometc ianbasiatgirp lc asgr ahsti nonsea sitesdi cDt eivsydenepehnohitariac tiar gtenbtdlittplts'sie taaSeees i iTnnae e,xdo ifdhe sh e.oxmeen sc ahetynfcp,gdedhhAed fapeteru d dnnleoieMhftlrePecwe eeFo tarl dd rfadree omceriatd esiso sduouwhsiciymkyn i n'h ksv g

oltmnhcagiderDinkouoerhn'ceaxs m dah sArhun hecsale svep rtorp t a hatono dsoy pper giittWeh aed hws i iwitFl eetarcips. eatwged

tdoe splnymet eaaldherfinnucreb tneI hd ,smrsu ,hwiekap “ltlo lilfyt d an.”yigto ai hlyiabnn ipigys hc hsaeei,In. nneda tsedoi“mitthlsaa' Scndt'di saaue”cei nrrvan

Please enable JavaScript to view this content.

2 Comments

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

  1. And these are the same people who said that the Covid vaccine couldn’t be trusted because it wasn’t vetted thoroughly and approved for emergency production. That there had not been enough time to study it’s effects. Right.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In